Target Identification and Validation

 

Finding novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry. It also remains a formidable challenge and companies continue to invest a lot of time and resources in identifying and validating targets that will yield viable drugs. What are the challenges in target discovery today? What new tools and strategies are being used to identify targets and how well are they working? What’s being done to adequately validate the targets once they are identified? What efforts are being taken to go after difficult or “undruggable” targets? Cambridge Healthtech Institute’s conference on Target Identification and Validation will bring together leading experts to discuss some of these critical issues. This is an unique opportunity to meet and network with biologists and screening groups from around the world to share ideas and set up collaborations.


Preliminary Agenda

TARGET DISCOVERY USING ADVANCED DISEASE MODELS

FEATURED PRESENTATION: CRISPR Screens in Challenging Model Systems
John Doench, PhD, Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

Aspartate/Aspergine Beta Hydroxylase (ASPH): A Potential Therapeutic Target for Overcoming HER2 Resistant Metastatic Breast Cancer
Geoffrey Bartholomeusz, PhD, Associate Professor and Director, Target Identification and Validation Program, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

CRISPR SCREENING FOR TARGET & OFF-TARGET IDENTIFICATION

An Evolutionary Cross-Species Approach to Context-Specifically Identify Essential Genes Using CRISPR Screens
Raghuvir “Ram” Viswanatha, PhD, Postdoctoral Research Fellow, Blavatnik Institute of Genetics, Harvard Medical School

Beyond Viability: Sensor-Based CRISPR Screening
Roderick Beijersbergen, PhD, Group Leader, Division of Molecular Carcinogenesis and NKI Robotics and Screening Center, The Netherlands Cancer Institute

Off-Target Toxicity is a Common Mechanism-of-Action of Cancer Drugs Undergoing Clinical Trials
Jason Sheltzer, PhD, Principal Investigator, Cold Spring Harbor Laboratory  

GENETICS-BASED TARGET IDENTIFICATION & VALIDATION

Human Genetics-Based Target Identification & Validation for 2x Success in the Clinic
Narender R. Gavva, PhD, Director, Early Target Discovery, Takeda California, Inc.

Genetic Studies of Multiple Sclerosis Risk and Progression for Drug Discovery
Paola Bronson, PhD, Scientist II, Human Target Validation Core (Translational Biology), Biogen Inc.

ARTIFICIAL INTELLIGENCE FOR TARGET DISCOVERY

Machine Learning-Based Methods to Prioritize Rational Drug Combinations
Arvind Rao, PhD, Associate Professor, Department of Computational Medicine and Bioinformatics, The University of Michigan, Ann Arbor

CASE STUDIES USING PHENOTYPIC SCREENING & CHEMICAL BIOLOGY APPROACHES

Hit Triage and Validation in Phenotypic Screening: Considerations & Strategies
Fabien Vincent, PhD, Associate Research Fellow, Hit Discovery and Lead Profiling Group, Pfizer

Comparison of Target Identification Approaches Using an IRAK4 Inhibitor
Jeff Martin, PhD, Scientist II, Chemical Biology & Proteomics, Biogen Inc.

Influence of Post-Translational Modifications, Metals and Partner Proteins on the Fe-S Cluster Synthesis Machinery
Jaimeen Majmudar, PhD, Senior Scientist, Chemical Biology, Pfizer, Inc.

Charles-River

Luncheon Presentation: A Blueprint for Translational Integrated Drug Discovery

John Montana, PhD, Corporate Vice President, Integrated Drug Development and Strategic Projects, Charles River

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/04/18
Event Information updated



Premier Sponsors

AbCellera
Ablexis Alivamab_stacked

Eurofins

Integral

OmniAb Ligand_Pharmaceuticals